Targovax (TRVX) Småprat

[Ramsess]

Jeg har stopploss på 4,99 i tilfelle et eller annet apokalyptisk skulle skje og jeg ikke hadde tilgang til data eller telefon

[RubenAyala]

Da hjelper det neppe med stopp loss heller.

[Ramsess]

Det kan jo være at zombie -apokalypsen begrenser seg til her på vestlandet.
Jeg sier selvsagt ikke at den starter her!

[RubenAyala]

Vestlandsfanden med andre ord ?

[Altiexiles]

Men det bekymrer meg at så mange mennesker vandrer hvileløst gjennom gatene med iphone, og kjøper laks og olje…
Det kan utvikle seg begge veier, men eg krysser fingrene for litt kreftmedisin nå, så får heller apokalypsen vente.

[Ramsess]

Enig!

[BioMed]

To norske biotekselskaper inngår lisensavtale til 100 millioner

[Martins]

Fint at vi holder oss i samme mønster, med unntak av salget av 9000 aksjer i sluttauksjonen til 10,26.
Vi får se hvor lenge det fortsetter å bevege seg på samme måte. Formasjonen må vel brytes etterhvert som tradere forsøker å utnytte den mer og mer?

[Klomp]

Ny dag, nye muligheter!

[BioMed]

I fra Twitter RADFORSK:

God morgen!

Jónas Einarsson og Elisabeth Andersen
spiller inn ny episode av podkasten Radium i morgen. Vi skal gå gjennom det som har skjedd på selskapsfronten de siste uken og vil gjerne ha spørsmål

[email protected]

[Chrysler300C]

Targovax er vel her denne uken , ifølge kalenderen dems

Scientific

Immuno-Oncology Summit Europe

[TekBot]

19/03-2019 11:58:38: (TRVX) Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring

Oslo, Norway, 19 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, announces that members of its senior management team is invited to
…

Vis børsmeldingen

present at upcoming conferences.
13th Annual BIO-Europe Spring, Vienna, Austria
Date: 25 March 2019
Presenter: Øystein Soug (CEO)
Panel discussion:

• Art of multitrack deal: Keys to maximizing the value of your company
• Time: 14:45 CET
  DNB’s 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, Norway
  Date: 4 April 2019
  Presenter: Øystein Soug (CEO)
  Presentation:
• Time: 13:45 CET
  3rd Annual European Neoantigen Summit, Amsterdam, The Netherlands
  Date: 25 April 2019
  Presenter: Erik Digman Wiklund (CBO)
  Presentation:
• Title: TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in
  Resected Pancreatic Cancer
• Time: 12:00 CET
  Presentations will be available to download at
  www.targovax.com (https://www.targovax.com/Investors/Events-and
  -Presentations/events/default.aspx) after the event.
  For further information, please contact:
  Renate Birkeli, Investor Relations
  Phone: +47 922 61 624
  Email: [email protected]
  Media and IR enquires:
  Andreas Tinglum - Corporate Communications
  Phone: +47 9300 1773
  Email: [email protected]
  ([email protected])
  About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

http://www.netfonds.no/quotes/release.php?id=20190319.OBI.20190319S35

[BioMed]

Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring

Oslo, Norway, [19 March 2019](calendar:T2:19 March 2019) - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team is invited to present at upcoming conferences.

13th Annual BIO-Europe Spring, Vienna, Austria
Date: [25 March 2019](calendar:T2:25 March 2019)
Presenter: Øystein Soug (CEO)

Panel discussion:

• Art of multitrack deal: Keys to maximizing the value of your company
• Time: 14:45 CET

DNB’s 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, Norway
Date: [4 April 2019](calendar:T2:4 April 2019)
Presenter: Øystein Soug (CEO)

Presentation:

• Time: 13:45 CET

3rd Annual European Neoantigen Summit, Amsterdam, The Netherlands
Date: [25 April 2019](calendar:T2:25 April 2019)
Presenter: Erik Digman Wiklund (CBO)

Presentation:

• Title: TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in Resected Pancreatic Cancer
• Time: 12:00 CET

Presentations will be available to download at www.targovax.com after the event.

[Chrysler300C]

Nå jobber robotene hardt igjen for og holde kursen nede med nedsalg i samme sekund som kjøp opp bull

Tror vi skal opp og teste 11 utover ettermiddagen !

[Whatsthat]

Tar gjerne 2% økning daglig jeg.

[Chrysler300C]

joda , helt enig! økningen er igrunn perfekt da vi ikke trenger noen pullbacks for og tette gap…

bare irriterer meg at handler som denne (25.000 aksjer) ser ut som stort nedsalg på kurven

[Krieghoff]

Tør vi håpe på TG data allerede 25 april? De skal vel være klar sånn ca da.

[Whatsthat]

Har sett “Mai” i slides tidligere…

[Krieghoff]

Utifra dagens medling så er TRVX blitt invitert til Holland. Arrangørem gjør vel neppe det om det ikke er interesse for TG og selskapet.

[Cinvest]

TG02 i Colorectal kan vell i praksis komme “når som helst”. Om jeg ikke husker feil, kom sist oppdatering tilbake i Desember 2017.

Targovax announces that TG02 has passed the initial safety review in the...